The nation of Zimbabwe has rejected a substantial US healthcare agreement worth $367m (272 million pounds) over five years over Washington's request for sensitive information.
This move became public after a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government representative later clarified that the US was demanding access to genetic material for scientific study and commercial purposes while was not willing to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued dialogue to find a agreement suitable to all parties so the nation's critical HIV treatment initiative can continue.
Broader Background
This development comes after a similar situation in Kenya, where a high court blocked a related deal with the US after legal challenges were filed about the safety of Kenyans' health data.
After returning to office recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government deals to boost openness and responsibility.
According to reports, Sixteen African countries have to date agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that might result from that provided information," he stated.
"Effectively, our country would supply the raw materials for scientific discovery with no certainty that the end products would be accessible to our population if a new disease outbreak arise."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting frameworks previously set up through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This system is intended to guarantee that when a country provides its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome ongoing discussions with our US partners on how future collaboration might be designed in a manner that respects the independence and dignity of both nations."
Health Experts Reaction
Medical experts said it acknowledged the government's concerns, but urged that talks must proceed since much of the country's HIV programmes depended on foreign aid.
"Where specific concerns arise, including those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it added.
The situation emphasises the ongoing tensions between accepting vital foreign assistance and safeguarding local interests in an increasingly data-driven world.